Neuropsychiatric Disorders and COVID-19: What We Know So Far
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) affects the central nervous system (CNS), which is shown in a significant number of patients with neurological events. In this study, an updated literature review was carried out regarding neurological disorders in COVID-19. Neurological s...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/9/933 |
| _version_ | 1797517641994207232 |
|---|---|
| author | Fernanda Majolo Guilherme Liberato da Silva Lucas Vieira Cetin Anli Luís Fernando Saraiva Macedo Timmers Stefan Laufer Márcia Inês Goettert |
| author_facet | Fernanda Majolo Guilherme Liberato da Silva Lucas Vieira Cetin Anli Luís Fernando Saraiva Macedo Timmers Stefan Laufer Márcia Inês Goettert |
| author_sort | Fernanda Majolo |
| collection | DOAJ |
| description | SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) affects the central nervous system (CNS), which is shown in a significant number of patients with neurological events. In this study, an updated literature review was carried out regarding neurological disorders in COVID-19. Neurological symptoms are more common in patients with severe infection according to their respiratory status and divided into three categories: (1) CNS manifestations; (2) cranial and peripheral nervous system manifestations; and (3) skeletal muscle injury manifestations. Patients with pre-existing cerebrovascular disease are at a higher risk of admission to the intensive care unit (ICU) and mortality. The neurological manifestations associated with COVID-19 are of great importance, but when life-threatening abnormal vital signs occur in severely ill COVID-19 patients, neurological problems are usually not considered. It is crucial to search for new treatments for brain damage, as well as for alternative therapies that recover the damaged brain and reduce the inflammatory response and its consequences for other organs. In addition, there is a need to diagnose these manifestations as early as possible to limit long-term consequences. Therefore, much research is needed to explain the involvement of SARS-CoV-2 causing these neurological symptoms because scientists know zero about it. |
| first_indexed | 2024-03-10T07:19:22Z |
| format | Article |
| id | doaj.art-79f7bd50687a4b768fc8ee09752b0cd1 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T07:19:22Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-79f7bd50687a4b768fc8ee09752b0cd12023-11-22T14:45:41ZengMDPI AGPharmaceuticals1424-82472021-09-0114993310.3390/ph14090933Neuropsychiatric Disorders and COVID-19: What We Know So FarFernanda Majolo0Guilherme Liberato da Silva1Lucas Vieira2Cetin Anli3Luís Fernando Saraiva Macedo Timmers4Stefan Laufer5Márcia Inês Goettert6Post-Graduate Program in Biotechnology, Universidade do Vale do Taquari-Univates, Lajeado 95914-014, Rio Grande do Sul, BrazilPostgraduate Program in Medical Sciences Center, Universidade do Vale do Taquari-Univates, Lajeado 95914-014, Rio Grande do Sul, BrazilPostgraduate Program in Medical Sciences Center, Universidade do Vale do Taquari-Univates, Lajeado 95914-014, Rio Grande do Sul, BrazilPost-Graduate Program in Biotechnology, Universidade do Vale do Taquari-Univates, Lajeado 95914-014, Rio Grande do Sul, BrazilPost-Graduate Program in Biotechnology, Universidade do Vale do Taquari-Univates, Lajeado 95914-014, Rio Grande do Sul, BrazilDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls Universität Tübingen, 72076 Tübingen, GermanyPost-Graduate Program in Biotechnology, Universidade do Vale do Taquari-Univates, Lajeado 95914-014, Rio Grande do Sul, BrazilSARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) affects the central nervous system (CNS), which is shown in a significant number of patients with neurological events. In this study, an updated literature review was carried out regarding neurological disorders in COVID-19. Neurological symptoms are more common in patients with severe infection according to their respiratory status and divided into three categories: (1) CNS manifestations; (2) cranial and peripheral nervous system manifestations; and (3) skeletal muscle injury manifestations. Patients with pre-existing cerebrovascular disease are at a higher risk of admission to the intensive care unit (ICU) and mortality. The neurological manifestations associated with COVID-19 are of great importance, but when life-threatening abnormal vital signs occur in severely ill COVID-19 patients, neurological problems are usually not considered. It is crucial to search for new treatments for brain damage, as well as for alternative therapies that recover the damaged brain and reduce the inflammatory response and its consequences for other organs. In addition, there is a need to diagnose these manifestations as early as possible to limit long-term consequences. Therefore, much research is needed to explain the involvement of SARS-CoV-2 causing these neurological symptoms because scientists know zero about it.https://www.mdpi.com/1424-8247/14/9/933angiotensin-converting enzyme 2 (ACE2)central nervous systemSARS-CoV-2 |
| spellingShingle | Fernanda Majolo Guilherme Liberato da Silva Lucas Vieira Cetin Anli Luís Fernando Saraiva Macedo Timmers Stefan Laufer Márcia Inês Goettert Neuropsychiatric Disorders and COVID-19: What We Know So Far Pharmaceuticals angiotensin-converting enzyme 2 (ACE2) central nervous system SARS-CoV-2 |
| title | Neuropsychiatric Disorders and COVID-19: What We Know So Far |
| title_full | Neuropsychiatric Disorders and COVID-19: What We Know So Far |
| title_fullStr | Neuropsychiatric Disorders and COVID-19: What We Know So Far |
| title_full_unstemmed | Neuropsychiatric Disorders and COVID-19: What We Know So Far |
| title_short | Neuropsychiatric Disorders and COVID-19: What We Know So Far |
| title_sort | neuropsychiatric disorders and covid 19 what we know so far |
| topic | angiotensin-converting enzyme 2 (ACE2) central nervous system SARS-CoV-2 |
| url | https://www.mdpi.com/1424-8247/14/9/933 |
| work_keys_str_mv | AT fernandamajolo neuropsychiatricdisordersandcovid19whatweknowsofar AT guilhermeliberatodasilva neuropsychiatricdisordersandcovid19whatweknowsofar AT lucasvieira neuropsychiatricdisordersandcovid19whatweknowsofar AT cetinanli neuropsychiatricdisordersandcovid19whatweknowsofar AT luisfernandosaraivamacedotimmers neuropsychiatricdisordersandcovid19whatweknowsofar AT stefanlaufer neuropsychiatricdisordersandcovid19whatweknowsofar AT marciainesgoettert neuropsychiatricdisordersandcovid19whatweknowsofar |